Emerging pathological diagnostic strategies for solid pseudopapillary neoplasm of the pancreas: insights from omics and innovative techniques
Open Access
- 1 May 2025
- journal article
- review article
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 11 (3) , e70029
Abstract
Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare, low‐grade malignant tumor, representing 0.9–2.7% of all exocrine pancreatic tumors. SPN patients generally have a favorable prognosis with a 5‐year survival rate exceeding 95% following complete surgical resection. Accurate diagnosis is crucial to avoid unnecessary treatments. Currently, SPN diagnosis relies on imaging techniques such as CT and MRI, along with immunohistochemical analysis of biopsy and resection samples. The main challenge in diagnosis is the potential inability to accurately identify recurrent or metastatic SPN, as well as ‘malignant’ SPN, due to the lack of specific biomarkers. Advances in high‐throughput omics technologies, including genomics, transcriptomics, proteomics and metabolomics, have opened new avenues for identifying novel biomarkers for SPN. Additional, liquid biopsy techniques have enabled more comprehensive analysis of biosamples such as pancreatic cyst fluid, offering promising prospects for preoperative diagnosis. This review highlights recent research on SPN diagnosis, focusing on immunohistochemical markers, tissue sampling methods and the potential of omics approaches. It also discusses the challenges and opportunities in improving diagnostic accuracy, particularly for high‐grade and metastatic SPNs.Keywords
This publication has 77 references indexed in Scilit:
- Discovered on gastrointestinal stromal tumor 1 (DOG1) is expressed in pancreatic centroacinar cells and in solid-pseudopapillary neoplasms—novel evidence for a histogenetic relationshipHuman Pathology, 2011
- Gene expression profiling provides insights into the pathways involved in solid pseudopapillary neoplasm of the pancreasThe Journal of Pathology, 2009
- The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasiaVirchows Archiv, 2008
- Array comparative genomic hybridization analysis of solid pseudopapillary neoplasms of the pancreasLaboratory Investigation, 2008
- Membrane loss and aberrant nuclear localization of E‐cadherin are consistent features of solid pseudopapillary tumour of the pancreas. An immunohistochemical study using two antibodies recognizing different domains of the E‐cadherin moleculeHistopathology, 2008
- Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11qLaboratory Investigation, 2007
- Clinically Aggressive Solid Pseudopapillary Tumors of the PancreasAmerican Journal of Surgical Pathology, 2005
- Significance of aberrant (cytoplasmic/nuclear) expression of beta‐catenin in pancreatoblastomaThe Journal of Pathology, 2002
- Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm.2001
- Solid-pseudopapillary tumor of the pancreas: its origin revisitedVirchows Archiv, 2000